Company intelligence / Profile preview

MIKAJAKI

Plan-les-Ouates, Geneva Canton, Switzerlandmikajaki.ai ↗

Ownership: Private
Development stage: Commercial

Overview

MIKAJAKI has developed and commercially launched a fully automated ophthalmic diagnostic platform in Europe. The system combines AI-driven virtual assessment, robotic scanning, and comprehensive reporting to deliver advanced eye health diagnostics efficiently. It is CE-marked and now available across the European market.

Therapeutic areas: Ophthalmology
Modalities: DeviceDigital health platform
Industry: Medical Imaging

Drug pipeline

1 asset

EyeLib

Commercial

Indications: Ophthalmology

Partnerships

Supported by Innosuissepowered by FONGIT

Beyond the preview

Go deeper on MIKAJAKI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MIKAJAKI.

Explore the full profile